Stem cell-derived retinal cells need primary cilia to support survival of light-sensing photoreceptors
Scientists at the National Eye Institute (NEI), part of the National Institutes of Health, report that tiny tube-like protrusions called primary cilia on cells of the retinal pigment epithelium (RPE)—a layer of cells in the back of the eye—are essential for the survival of the retina’s light-sensing photoreceptors. The discovery has advanced efforts to make stem cell-derived RPE for transplantation into patients with geographic atrophy, otherwise known as dry age-related macular degeneration (AMD), a leading cause of blindness in the U.S. The study appears in the January 2 Cell Reports.
“We now have a better idea about how to generate and replace RPE cells, which appear to be among the first type of cells to stop working properly in AMD,” said the study’s lead investigator, Kapil Bharti, Ph.D., Stadtman investigator at the NEI. Bharti is leading the development of patient stem cell-derived RPE for an AMD clinical trial set to launch in 2018.
In a healthy eye, RPE cells nourish and support photoreceptors, the cells that convert light into electrical signals that travel to the brain via the optic nerve. RPE cells form a layer just behind the photoreceptors. In geographic atrophy, RPE cells die, which causes photoreceptors to degenerate, leading to vision loss.
Bharti and his colleagues are hoping to halt and reverse the progression of geographic atrophy by replacing diseased RPE with lab-made RPE. The approach involves using a patient’s blood cells to generate induced-pluripotent stem cells (iPSCs), cells capable of becoming any type of cell in the body. iPSCs are grown in the laboratory and then coaxed into becoming RPE for surgical implantation.
Attempts to create functional RPE implants, however, have hit a recurring obstacle: iPSCs programmed to become RPE cells have a tendency to get developmentally stuck, said Bharti. “The cells frequently fail to mature into functional RPE capable of supporting photoreceptors. In cases where they do mature, however, RPE maturation coincides with the emergence of primary cilia on the iPSC-RPE cells.”
The researchers tested three drugs known to modulate the growth of primary cilia on iPSC-derived RPE. As predicted, the two drugs known to enhance cilia growth significantly improved the structural and functional maturation of the iPSC-derived RPE. One important characteristic of maturity observed was that the RPE cells all oriented properly, correctly forming a single, functional monolayer. The iPSC-derived RPE cell gene expression profile also resembled that of adult RPE cells. And importantly, the cells performed a crucial function of mature RPE cells: they engulfed the tips of photoreceptor outer segments, a pruning process that keeps photoreceptors working properly.
By contrast, iPSC-derived RPE cells exposed to the third drug, an inhibitor of cilia growth, demonstrated severely disrupted structure and functionality.
As further confirmation of their observations, when the researchers genetically knocked down expression of cilia protein IFT88, the iPSC-derived RPE showed severe maturation and functional defects, as confirmed by gene expression analysis. Tissue staining showed that knocking down IFT88 led to reduced iPSC-derived RPE cell density and functional polarity, i.e., cells within the RPE tissue pointed in the wrong direction.
Bharti and his group found similar results in iPSC-derived lung cells, another type of epithelial cell with primary cilia. When iPSC-derived lung cells were exposed to drugs that enhance cilia growth, immunostaining confirmed that the cells looked structurally mature.
The report suggests that primary cilia regulate the suppression of the canonical WNT pathway, a cell signaling pathway involved in embryonic development. Suppression of the WNT pathway during RPE development instructs the cells to stop dividing and to begin differentiating into adult RPE, according to the researchers.
The researchers also generated iPSC-derived RPE from a patient with ciliopathy, a disorder that causes severe vision loss due to photoreceptor degeneration. The patient’s ciliopathy was associated with mutations of cilia gene CEP290. Compared to a healthy donor, iPSC-derived RPE from the ciliopathy patient had cilia that were smaller. The patient’s iPSC-derived RPE also had maturation and functional defects similar to those with IFT88 knockdown.
Further studies in a mouse model of ciliopathy confirmed an important temporal relationship: Looking across several early development stages, the RPE defects preceded the photoreceptor degeneration, which provides additional insights into ciliopathy-induced retinal degeneration.
The Latest on: Dry age-related macular degeneration
- Preventing and Treating Macular Degeneration in the Elderlyon July 19, 2019 at 10:47 am
Age-related macular degeneration (AMD) tops the list as one of the top three ... According to the American Academy of Ophthalmologists, you can have dry or wet AMD vision loss, caused by either the ... […]
- Yellow lenses can help macular degenerationon July 19, 2019 at 8:51 am
I.L.B. ANSWER: Age-related macular degeneration is the leading cause of vision loss ... and since there is little effective treatment for the more common “dry” form of ARMD beyond vitamins and smoking ... […]
- Yellow lenses to the rescue for macular degenerationon July 18, 2019 at 10:00 pm
I.L.B. Answer • Age-related macular degeneration is the leading cause of vision loss ... and since there is little effective treatment for the more common “dry” form of ARMD beyond vitamins and ... […]
- Pixium Vision announced sustained success of its PRIMA System after 12-months in dry age-related macular degeneration patientson July 17, 2019 at 10:02 pm
Data confirm better than expected interim six-month results The system is sustainably well tolerated while preserving residual peripheral vision Some patients improve their ability to identify letters ... […]
- Dry Age-Related Macular Degeneration in the U.S. with Drug Sales - Forecast to 2024on July 11, 2019 at 5:12 pm
DUBLIN, July 11, 2019 /PRNewswire/ -- The "US Dry Age-Related Macular Degeneration Market and Competitive Landscape - 2019" report has been added to ResearchAndMarkets.com's offering. US Dry Age ... […]
- Dry Age-related Macular Degeneration: New Insightson July 2, 2019 at 4:56 pm
Effective communication from the healthcare professionals was found to reduce patient fears after they are diagnosed with the 'dry' form of age-related macular degeneration (AMD), revealed new study ... […]
- Global Age-Related Macular Degeneration (AMD) Therapeutics Market 2019-2023 | Development of Gene Therapy for AMD Devices to Boost Growth | Technavioon July 1, 2019 at 8:11 am
Segmentation analysis This market research report segments the global age-related macular degeneration (AMD) therapeutics market by type (wet AMD and dry AMD) and geographical regions (North America, ... […]
- Macular Degeneration Treatment Market size to Garner more than US$ 11.4 Bn by 2026on June 25, 2019 at 4:49 am
220.127.116.11. Global Macular Degeneration Treatment Market Revenue Share By Disease Indication in 2017 18.104.22.168. Dry Age-related Macular Degeneration Treatment 22.214.171.124. Wet Age-related Macular Degeneration ... […]
- “Age Related Macular Degeneration Market”on May 14, 2019 at 9:25 pm
Age-Related Macular Degeneration (AMD) Market Research Report: By Type (Wet AMD & Dry AMD), by Stages (Intermediate AMD, Early AMD, & Late AMD), by Age Group (Above 75, Above 60, & Above 40), by ... […]
- Catalyst Biosciences & Mosaic Biosciences Present Preclinical Data on Pegylated CB 2782 for the Treatment of Dry Age-Related Macular Degenerationon April 29, 2019 at 5:13 am
Catalyst Biosciences & Mosaic Biosciences Present Preclinical Data on Pegylated CB 2782 for the Treatment of Dry Age-Related Macular Degeneration A single intravitreal injection of 125 μg CB 2782-PEG ... […]
via Google News and Bing News